Appendix 4C and Quarterly Activities Report - September 2026

• HER2 Breast Cancer Phase 1b/2 Clinical Trial advances with site activation
• Central Ethics approval received for clinical trial commencement
• Nanoparticle manufacturing for MagSense® reestablished with CDMO
• $3.75m capital raise completed to fund clinical trial
• Cash balance increased to AU$2.186m at quarter end

Imagion Biosystems Ltd. has made significant strides in its HER2 Breast Cancer Phase 1b/2 clinical trial, with multiple sites selected and activation underway. Central Ethics approval has been secured, allowing for the commencement of the trial. The company has reestablished nanoparticle manufacturing for its MagSense® platform through partnerships with a CDMO. A $3.75m capital raise was completed to fund the clinical trial. The company's cash balance increased to AU$2.186m at the end of the quarter.

The company is focused on finalizing site contracts and activating the clinical trial across multiple sites in the USA.